Loading...
StocksRunner logo
 
 
Alkermes plc
31.31
-0.73%
 
ALKS Alkermes plc
Last Price
Change
31.31
 
-0.73%
 
 
 

 
Sentiment
 
 

28.57

26.01

27.62

30.39

 
 
1m
3m
6m
1y
 

Summary

Alkermes plc (ALKS) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Earnings are forecast to grow

 
 

Risk Level

 
StocksRunner
 

Alkermes plc (ALKS) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

3.33
 

StocksRunner

 Above analyst estimates

 
 

Rating

×
 

Rating

3.67
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 
 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

5.00
 

StocksRunner

 Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
67%
33%
100%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
67%
11%
Positive
Negative
6 out of 9
events present
1 out of 9
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Month Ago
28.53
+0.67%
 
Strong Earnings
2 Month Ago
28.34
-0.14%
 
Top Headlines

alkermes raises fy23 outlook following arbitration award from janssen agreements. ) increased its fy23 outlook by $425 million to reflect a final award the company received from arbitration proceedings

Tue Jun 6, 2023

Potential

mizuho maintains alkermes (alks) buy recommendation. fintel reports that on april 27 2023 mizuho maintained coverage of alkermes (nasdaq:alks) with a buy recommendation.

Fri Apr 28, 2023

Rating

hc wainwright & co. maintains alkermes (alks) neutral recommendation. fintel reports that on april 27 2023 hc wainwright &. co. maintained coverage of alkermes (nasdaq:alks) with a neutral recommendation.

Fri Apr 28, 2023

Rating

alkermes (alks) q1 earnings & revenues beat estimates. alkermes plcalks reported first-quarter 2023 adjusted earnings of 1 cent per share which beat the zacks consensus estimate and our model estimate of a loss of 3 cents . the company

Thu Apr 27, 2023

Earnings

alkermes (alks) surpasses q1 earnings and revenue estimates. alkermes (alks) came out with quarterly earnings of $0.01 per share beating the zacks consensus estimate of a loss of $0.03 per share. this compares to earnings of $0.12 per

Wed Apr 26, 2023

Earnings

alkermes q1 adj. profit declines. reiterates 2023 financial expectations. (rttnews) - alkermes plc (alks) reported a first quarter net loss of $41.8 million or a loss per share of $0.25 compared to a gaap net loss of $35.9 million or a loss per

Wed Apr 26, 2023

Earnings

jp morgan maintains alkermes (alks) neutral recommendation. fintel reports that on april 25 2023 jp morgan maintained coverage of alkermes (nasdaq:alks) with a neutral recommendation.

Wed Apr 26, 2023

Rating

a preview of alkermess earnings. ) is set to give its latest quarterly earnings report on wednesday 2023-04-26. here'.s what investors need to know before the announcement. analysts estimate that alkermes will report an alkermes s will hope to hear

Tue Apr 25, 2023

Activity

alkermes receives second interim award in janssen pharmaceutica arbitration. (rttnews) - ireland-headquartered alkermes plc (alks) a fully integrated global biopharmaceutical company on tuesday announced that on april 19 2023 it received a secon

Tue Apr 25, 2023

Activity

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ALKS alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ALKS Alkermes plc

Last Price
31.31
Change
-0.73%
 

Summary

Alkermes plc (ALKS) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time

 
 
28.57
26.01
27.62
30.39
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Earnings are forecast to grow

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
33%
100%
100%
On Track
On Track
On Track
 
67%
11%
Positive
Negative
6 out of 9
events present
1 out of 9
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

3.33
 

StocksRunner

 Above analyst estimates

 
 

Rating

×
 

Rating

3.67
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 
 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

5.00
 

StocksRunner

 Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Alkermes plc (ALKS) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Month Ago
28.53
+0.67%
 
Strong Earnings
2 Month Ago
28.34
-0.14%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ALKS Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines